Subtype-specific patterns in HIV type 1 reverse transcriptase and protease in Oyo State, Nigeria: Implications for drug resistance and host response

AIDS Research and Human Retroviruses

Volumn 22, Issue 8, 2006, Pages 770-779

  Ojesina, Akinyemi I ^a   Sankalé, Jean Louis ^a   Odaibo, Georgina ^b   Langevin, Stanley ^a   Meloni, Seema T ^a   Sarr, Abdoulaye Dieng ^a   Olaleye, David ^b   Kanki, Phyllis J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; HLA A2 ANTIGEN; HLA B35 ANTIGEN; HLA B7 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT;

ARTICLE; CODON USAGE; CYTOTOXIC T LYMPHOCYTE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAXIMUM LIKELIHOOD METHOD; NIGERIA; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; VIRUS MUTATION; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; CLASSIFICATION; DRUG EFFECT; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; MOLECULAR GENETICS; SPECIES DIFFERENCE; STRUCTURAL GENE; VIROLOGY;

AMINO ACID SEQUENCE; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENES, POL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR SEQUENCE DATA; NIGERIA; PHYLOGENY; POLYMORPHISM, GENETIC; SPECIES SPECIFICITY;

EID: 33748750913     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.770     Document Type: Article

References (58)

1. Mansky LM: Retro virus mutation rates and their role in genetic variation. J Gen Virol 1998;79:1337-1345.
2. Preston BD: Error-prone retrotransposition: Rime of the ancient mutators. Proc Natl Acad Sci USA 1996;93:7427-7431.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
4. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
5. Robertson DL, Sharp PM, McCutchan FE, and Hahn BH: Recombination in HIV-1. Nature 1995;374:124-126.
6. Wolinsky SM, Korber BT, Neumann AU, et al.: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-542.
7. Kantor R and Katzenstein D: Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003;5:25-35.
8. Howard TM, Olaleye DO, and Rasheed S: Sequence analysis of the glycoprotein 120 coding region of a new HIV type 1 subtype A strain (HIV-1IbNg) from Nigeria. AIDS Res Hum Retroviruses 1994;10:1755-1757.
9. Agwale SM, Zeh C, Robbins KE, et al.: Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine 2002;20:2131-2139.
10. McCutchan FE, Carr JK, Bajani M, et al.: Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology 1999;254:226-234.
11. Montavon C, Toure-Kane C, Liegeois F, et al.: Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG. J Acquir Immune Defic Syndr 2000;23:363-374.
12. Peeters M, Esu-Williams E, Vergne L, et al.: Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses 2000;16:315-325.
13. Yeni PG, Hammer SM, Hirsch MS, et al.: Treatment for adult HIV infection: 2004 recommendations of the International ADDS Society-USA Panel. JAMA 2004;292:251-265.
14. Idigbe EO, Adewole TA, Eisen G, et al.: Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: A preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005;40:65-69.
15. Laurent C, Diakhate N, Gueye NF, et al.: The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS 2002;16:1363-1370.
16. Kantor R, Katzenstein DA, Efron B, et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2:e112.
17. Adje-Toure C, Bile CE, Borget MY, et al.: Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2003;34:111-113.
18. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, and Eshleman SH: Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses 2000;16:807-813.
19. Gordon M, De Oliveira T, Bishop K, et al.: Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: Implications for vaccine and antiretroviral control strategies. J Virol 2003;77:2587-2599.
20. Handema R, Terunuma H, Kasolo F, et al.: Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses 2003;19:151-160.
21. Konings FA, Zbong P, Agwara M, et al.: Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retroviruses 2004;20:105-109.
22. Pillay C, Bredell H, McIntyre J, Gray G, and Morris L: HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res Hum Retroviruses 2002;18:605-610.
23. Vicente AC, Agwale SM, Otsuki K, et al.: Genetic variability of HIV-1 protease from Nigeria and correlation with protease inhibitors drug resistance. Virus Genes 2001;22:181-186.
24. Shafer RW: Genotypic testing for HIV-1 drug resistance (November 30, 2003). http://hivdb.stanford.edu/modules/lookUpFiles/pdf/GenotypicResistance. pdf. Accessed February 17, 2004.
25. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, and Higgins DG: The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.
26. Posada D and Crandall KA: MODELTEST: Testing the model of DNA substitution. Bioinformatics 1998;14:817-818.
27. Swofford DL: PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods), Version 4. Sinauer Associates, Sunderland, MA, 2001.
28. McCormack GP and Clewley JP: The application of molecular phylogenetics to the analysis of viral genome diversity and evolution. Rev Med Virol 2002;12:221-238.
29. Maddison WP and Maddison DR: Interactive analysis of phylogeny and character evolution using the computer program MacClade. Folia Primatol (Basel) 1989;53:190-202.
30. Blom N, Gammeltoft S, and Brunak S: Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999;294:1351-1362.
31. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, and Brunak S: Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 2004;4:1633-1649.
32. Kennelly PJ and Krebs EG: Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. J Biol Chem 1991;266:15555-15558.
33. Brander C and Goulder PJR: The identification of optimal HIV-derived CTL epitopes in diverse populations using HIV clade-specific consensus. In: HIV Molecular Immunology 2001 (Korber BT, Brander C, Haynes BF, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2001, pp. I-1-20.
34. McClure MA, Johnson MS, Feng DF, and Doolittle RF: Sequence comparisons of retroviral proteins: Relative rates of change and general phylogeny. Proc Natl Acad Sci USA 1988;85:2469-2473.
35. Hue S, Clewley JP, Cane PA, and Pillay D: HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS 2004;18:719-728.
36. Leitner T, Kumar S, and Albert J: Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history. J Virol 1997;71:4761-4770.
37. Kijak GH, Currier JR, Tovanabutra S, et al.: Lost in translation: Implications of HIV-1 codon usage for immune escape and drug resistance. AIDS Rev 2004;6:54-60.
38. Dumans AT, Soares MA, Machado ES, et al.: Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis 2004;189:1232-1238.
39. Loemba H, Brenner B, Parniak MA, et al.: Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002;46:2087-2094.
40. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Drug resistance mutations in HIV-1. Top HIV Med 2003;11:215-221.
41. Prater AJ, Beardall A, Ariyoshi K, et al.: Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001;15:1493-1502.
42. Turner D, Brenner B, Moisi D, et al.: Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:2993-2998.
43. Haneda E, Furuya T, Asai S, Morikawa Y, and Ohtsuki K: Biochemical characterization of casein kinase II as a protein kinase responsible for stimulation of HIV-1 protease in vitro. Biochem Biophys Res Commun 2000;275:434-439.
44. Harada S, Haneda E, Maekawa T, et al.: Casein kinase II (CK-II)-mediated stimulation of HIV-1 reverse transcriptase activity and characterization of selective inhibitors in vitro. Biol Pharm Bull 1999;22:1122-1126.
45. Idriss H, Kawa S, Damuni Z, Thompson EB, and Wilson SH: HIV-1 reverse transcriptase is phosphorylated in vitro and in a cellular system. Int J Biochem Cell Biol 1999;31:1443-1452.
46. Lazaro JB, Boretto J, Selmi B, Capony JP, and Canard B: Phosphorylation of AZT-resistant human immunodeficiency virus type 1 reverse transcriptase by casein kinase II in vitro: Effects on inhibitor sensitivity. Biochem Biophys Res Commun 2000;275:26-32.
47. Okoye RC, Williams E, Alonso A, et al.: HLA polymorphisms in Nigerians. Tissue Antigens 1985;25:142-155.
48. Uko GP, Asuquo MA, Dawkins RL, Udim ER, Banjoko SO, and Jaja O: HLA class I phenotype and gene frequencies in parts of southern Nigeria. Dis Markers 1997;13:123-129.
49. Cao H, Kanki P, Sankale JL, et al.: Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997;71:8615-8623.
50. Kawana A, Tomiyama H, Takiguchi M, Shioda T, Nakamura T, and Iwamoto A: Accumulation of specific amino acid substitutions in HLA-B35-restricted human immunodeficiency virus type 1 cytotoxic T lymphocyte epitopes. AIDS Res Hum Retroviruses: 1999;15:1099-1107.
51. Tomiyama H, Miwa K, Shiga H, et al.: Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B3501 molecules that are associated with the accelerated progression of AIDS. J Immunol 1997;158:5026-5034.
52. Karlsson AC, Deeks SG, Barbovir JD, et al.: Dual pressure from antiretroviral therapy and cell-mediated immune response on the 1 human immunodeficiency virus type 1 protease gene. J Virol 2003;77:6743-6752.
53. Kaul R, Dong T, Plummer FA, et al.: CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001;107:1303-1310.
54. Wainberg MA: HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004;18:S63-68.
55. Winkler CA and O'Brien SJ: Effect of genetic variation on HIV transmission and progression to AIDS. In: AIDS in Africa, 2nd ed. (Essex M, Mboup S, Kanki PJ, Marlink RG, and Tlou SD, eds.). Kluwer Academic, New York, 2002, pp. 52-73.
56. Imanishi T, Akaza T, Kimura A, Tokunaga K, and Gojobori T: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: HLA 1991, Vol. 1 (Tsuji K, Aizawa M, and Sasazuki T, eds). Oxford University Press, Oxford, 1992, pp. 1065-1220.
57. Moore CB, John M, James IR, Christiansen FT, Witt CS, and Mallal SA: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296:1439-1443.
58. Koch N, Yahi N, Ariasi F, Fantini J, and Tamalet C: Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy. J Clin Microbiol 1999;37:1595-1597.